Engineering Confidence for
Monoclonal Antibody
Programs
Specialized in Monoclonal Antibody Development, CMC Strategy, and Biologics Manufacturing Support,
from early-stage IND-enabling work to commercial readiness.
IND–BLA
ICH
mAb CMC Consulting
Comprehensive
Support Across the
mAb Development
Lifecycle
DES Pharma supports monoclonal antibody programs across full-length IgG molecules, engineered antibody variants, fragments, bispecific formats, and related recombinant antibody products.
Our teams understand how early choices around isotype, expression system, and product profile influence manufacturability, analytical strategy, and long-term development planning. We help clients build practical CMC paths around common mAb platforms, including CHO-based production, clone selection, upstream optimization, downstream purification, and phase-appropriate formulation planning.
mAb Platform Expertise
Formats, expression systems & CQA strategy
Formats & Modalities
- Full-length IgG
- Bispecific Antibodies
- Antibody Fragments
- Engineered Variants
- Recombinant mAbs
Expression & Platform
- CHO Cell Lines
- Clone Selection
- Fed-Batch Upstream
- Protein A Capture
- Polishing Chromatography
Critical Quality Attributes
- Aggregation (SEC-MALS)
- Charge Variants (icIEF)
- Glycan Profiling
- Potency Assays
- Sequence Variants
What We DomAb Services Across the Development Continuum
From cell line development through commercial readiness, our consultants work inside your CMC team to
keep timelines moving and regulatory packages strong.
Program & Process Development
End-to-end mAb process development support, from expression system selection through commercial-scale process characterization and validation readiness.
- mAb cell line development & CHO upstream optimization
- Protein A capture strategy & polishing process design
- Formulation development & excipient selection
- Scale-up support from bench to manufacturing scale
- Process characterization & design of experiments (DoE)
Analytical Development & QC
Specialized mAb characterization and analytical method development aligned with ICH Q6B specifications and phase-appropriate regulatory expectations.
- Potency assay development & qualification
- Charge variant analysis: icIEF, CEX-HPLC
- Glycan profiling & glycoform characterization
- Peptide mapping & sequence variant analysis
- SEC-MALS aggregation assessment
- Stability-indicating method development
Supply Chain & Procurement
Strategic supply chain planning for mAb manufacturing, ensuring material availability, CDMO alignment, and cold-chain integrity across clinical and commercial programs.
- Bioreactor consumables sourcing & qualification
- Raw material qualification & vendor management
- CDMO selection: upstream, downstream, fill-finish
- Cold-chain planning for mAb drug product
- Single-use technology assessment
Quality Assurance
mAb-focused GMP quality support aligned with FDA biologics expectations and ICH Q5E comparability requirements, from Phase 1 through commercial lifecycle management.
- Batch release strategy & lot disposition support
- Comparability planning per ICH Q5E
- Change control & variation management
- Stability oversight & expiry justification
- Quality systems for clinical & commercial GMP
Phase-Appropriate Support
Where Are You in Your mAb
Program?
We calibrate our CMC consulting to your development stage, from the first IND-enabling study to post-approval lifecycle management.
Pre-Clinical / IND-Enabling
CMC strategy for your first-in-human submission, covering process definition, initial characterization, and IND-ready documentation.
- CHO cell line development & clone selection
- Preliminary upstream & downstream process definition
- Phase 1 reference standard & stability initiation
- IND CMC section authoring & review
- Risk-based CQA & CPP identification
Phase 1–2 Clinical
Finalize your manufacturing process, expand analytical characterization, and build a robust CMC package for IND amendments and dose escalation.
- Process optimization & scale-up from DS to DP
- Extended analytical characterization per ICH Q6B
- IND amendment preparation & Type B/C meeting support
- Phase-appropriate specification development
- CDMO technology transfer support
Phase 2 Pivotal / Phase 3
Prepare your PPQ briefing book, finalize commercial process, and build comparability packages for any process changes implemented since Phase 1.
- Process characterization studies & DoE planning
- PPQ protocol preparation & execution oversight
- ICH Q5E comparability strategy & execution
- Commercial specification setting
- Pre-BLA meeting briefing book preparation
BLA / Commercial Filing
CMC authoring, BLA Module 3 assembly, and post-approval lifecycle planning for commercial mAb programs.
- BLA Module 3 / CTD Section 3.2.S & 3.2.P authoring
- PPQ completion reporting & AQbD documentation
- Post-approval change management strategy
- Commercial stability program oversight
- Lifecycle CMC planning & variation filing strategy
Ongoing Lifecycle & Post-Approval
Manufacturing site changes, analytical method transfers, and post-approval comparability exercises require technically rigorous CMC packages. We support sponsors navigating these changes efficiently.
- Site change comparability per ICH Q5E
- Analytical method transfer & validation
- Raw material change evaluation & qualification
- Annual Product Review support
- Facility fit & tech transfer to new CDMOs
- Shelf-life extension data packages
Our mAb Expertise Deep Technical Knowledge Across the mAb Platform
DES Pharma’s mAb practice is built around the quality attributes and manufacturing decisions that determine whether a program succeeds at scale. For most molecules, that means .building control strategies around aggregation, charge heterogeneity, glycosylation patterns, sequence variants, potency, and stability, connecting those attributes to the upstream and downstream process choices that drive them. We work across CHO cell culture platforms, Protein A chromatography strategies, and downstream polishing approaches to ensure that process development decisions are traceable to product quality outcomes.
Our analytical support uses methods including SEC-MALS for aggregation, icIEF for charge variant profiling, glycan mapping for Fc-related quality attributes, and potency assays calibrated to the product mechanism and development stage. Characterization work is structured against ICH Q6B expectations for biotechnological products, with comparability planning aligned to ICH Q5E and viral safety documentation aligned to ICH Q5A where applicable.
We help sponsors build technically sound, phase-appropriate CMC packages from IND-enabling work through commercial readiness, including FDA BLA support, post-approval change management, and lifecycle planning when manufacturing, testing, or site strategy evolves.
Upstream Process Development
CHO cell line development, fed-batch optimization, dissolved oxygen control, temperature shift strategies, and bioreactor scale-up design for mAb titer and quality.
Downstream Purification
Protein A affinity capture, viral clearance design, polishing by ion exchange and HIC, UF/DF optimization, and step yield / impurity clearance characterization.
Analytical Characterization
Comprehensive characterization per ICH Q6B: peptide mapping, glycan analysis, charge variants, aggregation, potency, and higher-order structure to support specifications and CQA risk assessment.
Comparability & Lifecycle
ICH Q5E-aligned comparability studies for process changes, site transfers, and scale-up events, with documentation strategies designed to support BLA supplements and MAA variations.
BLA-Ready CMC Documentation
Module 3 authoring, specification package development, PPQ reporting, and pre-BLA meeting preparation calibrated to FDA CDER/CBER expectations for licensed biologics.
Why DES Pharma What Sets Our mAb Practice Apart
Our consultants bring hands-on experience from mAb development programs across multiple platforms, sponsors, and CDMOs, so we know where programs get stuck and how to keep them moving.
Platform-Specific Technical Depth
Our team understands CHO biology, Protein A chromatography, aggregation kinetics, and mAb glycosylation in a way that generalist consultants cannot replicate. We bring modality-specific judgment to every engagement.
Regulatory-First Documentation
Every CMC deliverable is built with the reviewer in mind. We write IND sections, BLA modules, and briefing books that anticipate agency questions and reduce information request cycles.
Process–Analytical Integration
We connect your upstream and downstream development work directly to your analytical characterization and control strategy, ensuring CQAs are understood mechanistically, not just measured.
Phase-Appropriate Efficiency
We resist the temptation to over-engineer early-stage programs. Our recommendations are calibrated to development stage, helping you invest development resources where they create the most value.
CDMO Navigation & Oversight
We know how CDMOs work: their capabilities, constraints, and communication styles. We help you select the right manufacturing partners and maintain technical oversight throughout the relationship.
Lifecycle & Change Management
mAb programs evolve. We support comparability exercises, site change management, and post-approval variations with the scientific rigor and documentation quality regulators expect.
Our Approach How We Engage on mAb Programs
We begin by understanding your program’s specific context (molecule, stage, regulatory history, and team) before recommending a CMC strategy. Our engagements are structured, transparent, and aligned to
deliverables that move your program forward.
Program Assessment & Gap Analysis
We review your existing CMC documentation, process data, and analytical package to identify gaps relative to phase-appropriate expectations and your target regulatory pathway (BLA, MAA, or hybrid).
CMC Strategy Development
We define a fit-for-purpose CMC roadmap covering process development milestones, analytical method plan, specification development strategy, and regulatory filing timeline — integrated with your clinical plan.
Technical Execution & Oversight
Our consultants can lead, support, or oversee specific workstreams, from writing study protocols and directing CDMO activities to reviewing analytical data and authoring CMC sections in real time.
Regulatory Submission Support
We prepare, review, and respond to IND submissions, IND amendments, BLA modules, and agency meeting packages, with the documentation quality that reflects positively on your program.
Regulatory References
ICH Q6B
Specifications for Biotechnological & Biological Products: anchor for mAb characterization and specification strategy.
ICH Q5E
ICH Q8
ICH Q11
FDA Guidance
Get Started Ready to Strengthen Your mAb CMC Strategy?
Whether you’re preparing your first IND or finalizing a BLA submission, our consultants are ready to assess your
program and identify the highest-value areas for support.